Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Net Margin (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Net Margin for 14 consecutive years, with 0.41% as the latest value for Q2 2025.

  • Quarterly Net Margin rose 890.0% to 0.41% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 0.19% through Dec 2025, up 236.0% year-over-year, with the annual reading at 0.93% for FY2025, 603.0% up from the prior year.
  • Net Margin for Q2 2025 was 0.41% at Aytu Biopharma, up from 0.29% in the prior quarter.
  • The five-year high for Net Margin was 2.3% in Q3 2024, with the low at 220.22% in Q1 2022.
  • Average Net Margin over 5 years is 36.55%, with a median of 8.4% recorded in 2023.
  • The sharpest move saw Net Margin plummeted -14801bps in 2021, then soared 18855bps in 2023.
  • Over 5 years, Net Margin stood at 49.94% in 2021, then skyrocketed by 49bps to 25.47% in 2022, then skyrocketed by 82bps to 4.48% in 2023, then soared by 117bps to 0.76% in 2024, then crashed by -46bps to 0.41% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 0.41%, 0.29%, and 0.76% for Q2 2025, Q1 2025, and Q4 2024 respectively.